Polymorphonuclear leukocytes (PMN) and monocytes from 20 patients with acute bacterial infections were examined for phagocytic function. PMN of patients expressed markedly enhanced phagocytosis as measured by the ingestion of erythrocyte (E)IgG and IgG/C3b-coated E. Phagocytosis of E coated with C3b alone was not seen, while low levels of ingestion of iC3b-E by patients' PMNs was noted. Monocytes from patients and controls expressed similar phagocytic activity in a fixed endpoint assay; however, the kinetics of phagocytosis by patients' monocytes was strikingly faster. Superoxide anion (02) and myeloperoxidase activities were similar to controls in PMN of four patients studied on day 1 of admission.
Introduction
Phagocytosis by PMN constitutes a critical mechanism of host defense against bacterial infection. Many in vitro studies have detailed changes in the state of activation and function of normal PMN in response to inflammatory and infectious stimuli (1, 2) . What happens to PMN in patients with acute bacterial infections is less clear. Both increased (3, 4) , normal and decreased (5, 6) phagocytic capabilities of PMN in patients with infection have been reported. In general, these studies used serum-opsonized particles as phagocytic targets. With the recognition that there exist multiple types of independently functioning, specific receptors for individual ligands on target par-ticles, it was of importance to reexamine this question using highly defined target particles. This paper reports results of studies designed to assess the state of activation of PMN and monocytes with regard to phagocytosis in a receptor-specific fashion. The target particles consisted of sheep erythrocytes coated with known quantities of IgG (EIgG),' C3b (EAC3b), or iC3b (EAC3bi), or with known amounts of IgG plus C3b (EAC3b-IgG).
In a recent report, we showed that adherent PMN from normal, healthy individuals do not express a full phagocytic potential for EIgG when studied in media without scavengers of products of the oxidative burst (7) . Phagocytic activity of PMN from normal individuals was markedly enhanced by sodium azide or catalase, which are inhibitors of various steps in the oxidative burst. This enhancement of phagocytosis by sodium azide was also shown with serum-opsonized Candida. PMN from chronic granulomatous disease (CGD) patients and from one patient with myeloperoxidase (MPO) deficiency showed markedly enhanced phagocytosis in comparison to normal PMN (7) . These findings indicated that products of oxidative respiration regulate the phagocytic uptake of IgGsensitized targets in normal PMN and suggested that the degree of ingestion of targets is under physiologic control. It was of great interest to determine whether the phagocytic response of PMN from infected individuals was similar to that of normal controls. Moreover, we wished to determine whether the apparent normal downregulation of PMN during phagocytosis of IgG-sensitized targets was fully or partially reversed in PMN of infected patients. Studies in 20 infected patients and controls revealed markedly increased phagocytic capacity of patient PMN as evidenced by their enhanced ability to ingest EIgG and EAC3b-IgG in the absence of an inhibitor of the oxidative burst. This marked upregulation was not associated with alterations in the number of low affinity Fc receptors (FcRII or FcRIII), or of the important opsonic complement receptors, CR1 or CR3. Increased numbers of FcRI, however, were seen on the surface of PMN from five of seven infected patients studied.
In addition, longitudinal studies conducted on three patients with acute bacterial infection demonstrated marked upregulation of PMN phagocytosis concordant with the infectious process. In this study, we report an analysis of phagocytic capability as it relates to the kinetics of phagocytosis, MPO release, and superoxide anion production, and the expression of FcR (I, II and III), CR1, and CR3 in a series of individuals with documented severe bacterial infections.
Methods
Buffers and media. Veronal-buffered saline (VBS) low ionic-strength buffer containing 60% dextrose in VBS (DVBS), and VBS containing 10 mM EDTA (EDTA-VBS) were prepared as previously described (8, 9) . HBSS without Ca2l and Mg2" and RPMI 1640 containing L-glutamine were obtained from Gibco Laboratories, Grand Island, NY. PBS containing 1 mg/ml gelatin, 10 mM EDTA and 0.05% sodium azide (PBS-G) was prepared as previously described (10) (15) . 1B4, which recognizes CRI, was prepared as previously described ( 16) . Fab fractions were prepared from both of these MAbs by published methods (17) . IgG fractions of IV-3, a MAb that recognizes the PMN low affinity FcRII (18) MAbs were radiolabeled with 25I using the lodobead iodination procedure (14) . The specific activities of the MAbs were: IB4: 1.5 ,gCi/hg, anti-Mol:0.27 gCi/,g, 3G8:0.50 tiCi/yg; IV-3 1.10 I Ci/og; 32 12 X 75 mm polypropylene tubes, followed by the addition of 1251 monomeric IgG. In parallel, 1251 monomeric IgG was added in the presence of 50-100-fold excess of unlabeled monomeric IgG. The volume in each tube was equalized with PBS-G and the cells were incubated for 30 min at 37°C. The cells were then pelleted by centrifuging through an oil mixture consisting of one part bis-2-(ethylhexyl) phthalate to three parts dibutyl phthalate. Bound monomeric IgG was determined from the level of radioactivity in the cell pellets and specific binding was calculated by subtracting '251I-IgG bound in the presence of 50-100-fold excess unlabeled IgG. In the 125I-MAb binding assays, 100
Al of PMN suspended in HBSS at 20 X 106/ml was incubated at 0°C for 1 h with '25I-MAb. In control tubes '251-MAb was added in the presence of 50-100-fold excess of unlabeled MAb. The remainder of the assay was as described for 125-monomeric IgG binding.
Myeloperoxidase release. These assays were performed as previously described (24), using 96-well U-shaped Immulon 1 microtiter plates (Dynatech Laboratories, Chantilly, VA). PMN at 8 X 106/ml were pretreated with cytochalasin B (5 Ag/ml) immediately before 25 Ml of the PMN was added to each well. The microtiter plates were then incubated for 30 min at 37°C in a 5% CO2 incubator. 50 Ml of 0.2 M sodium phosphate buffer, pH 6.2, was then added followed by 25 Ml of a solution containing equal parts of 15 mM H202 combined with 3.9 mM 3'3' dimethoxybenzidine. A visible color reaction was stopped after 15 min at room temperature by 1% sodium azide. The optical density was assayed at 490 and 630 nM on an MR580 model microelisa automatic reader (Dynatech Laboratories). Assays were carried out on resting PMN, PMN pretreated with 10 mM sodium azide, and PMN plus 10 Ml 10% Triton X-100 to measure total MPO present.
Superoxide anion production. The amount of superoxide anion generated was assayed by measurement of the reduction of ferricytochrome c (25) . Assays were performed in 96-well flat bottom plates (Costar, Cambridge, MA). 100 Ml of cytochrome-c, with and without PDBu at 100 ng/ml, was added to each chamber and 5,ul of superoxide dismutase (60,000 U/ml) was added to control chambers. After the addition of 100 Ml of PMN at S X 105/ml, the plate was incubated for 60 min at 37°C in a 5% CO2 incubator. Optical density was assayed at 550 nM on a dual beam microplate reader (model MR600; Dynatech Laboratories). Production of superoxide anion was determined using the molar extinction coefficient of cytochrome c (6.3 with a light path of 3 mm).
Statistical analysis. Phagocytosis and kinetic experiments were analyzed using two-way analysis of variance (ANOVA) unless otherwise stated. The binding of monomeric IgG, monoclonal antibodies, MPO release, and superoxide anion production were analyzed using the paired sample t test. Values of P < 0.05 were considered statistically significant.
Results
Phagocytosis in the absence of sodium azide. Phagocytosis assays were performed to determine if the PMN of acutely infected patients would ingest IgG-coated particles under conditions in which there was only minimal ingestion by control PMN (7). The results after 40 min of phagocytosis are shown in Fig. 1 .
In the absence of sodium azide, the percentage of patient PMN ingesting EIgG at 1/2,000, 1/4,000, and 1/8,000 dilutions of IgG were: 37.64±7.16%, 14.75±4.80%, and 7.36±4.11%, respectively. The percent phagocytosis by cells from normal controls in these experiments was 0-6% (n = 14 for patients, n = 12 for controls; P < 0.002 at 1/2,000; P < 0.04 at 1/4,000, P = NS at 1/8,000 comparing patients with controls using the Bonferroni inequality for multiple testing) (26 The amount of phagocytosis by PMN from patients and controls correlated directly with the IgG concentration used to opsonize either E or EAC3b (Table II) . The concentrations of IgG used to study PMN phagocytic activity ranged from 1/2,000 to 1/16,000 corresponding to 18,000 and 2,250 IgG molecules/RBC, respectively. Differences in phagocytosis at the varying IgG levels was significant (P < 0.001 by two-way ANOVA for both PMN and monocytes from patients and controls). As expected, C3b enhanced the IgG-triggered ingestion of opsonized targets by PMN, primarily at lower concentrations of IgG. Notably, in the absence of IgG, E and EAC3b were not ingested by control or patient PMN and azide did not induce the ingestion of these target cells.
Phagocytosis by monocytes. Investigations were carried out to determine if PMN and monocytes behaved differently with regard to phagocytosis in patient and control subjects. Prior experiments showed that incubation of normal monocytes with sodium azide had no effect on phagocytosis by these cells (unpublished findings). In striking contrast to PMN, phagocytosis of EIgG by patient and control monocytes was similar when overall phagocytic capacity was examined. As shown in Table II , the mean percent phagocytosis over time by monocytes of three patients studied was similar to that of the controls at each concentration of IgG used to opsonize the erythrocytes. PMN from these same patients expressed an upregulation in phagocytosis similar to that of other patients studied.
Phagocytosis of EAC3bi. CR3-mediated phagocytosis as assessed by the ingestion of EAC3bi was also assayed in the presence and absence of sodium azide (Table III) . Approximately 9% of PMN from seven patients studied ingested EAC3bi in the absence of added azide, in comparison to < 1% of control PMN. This represented a significant difference in both the percentage of phagocytosis and the PI value. In the presence of azide, phagocytosis by patient and control PMN increased; however there was no significant difference between phagocytosis by patients and controls with azide present.
Kinetics ofphagocytosis. The kinetics of phagocytosis was assayed by stopping phagocytosis at five time points (from 5 to 40 min) as described in Methods. In Table IV , kinetics is expressed as the time necessary to achieve one-half the maximum amount of phagocytosis. IgG dilutions for PMN + 10 (Table IV) . Longitudinal studies. From a subset of patients (n = 3), longitudinal studies were performed using PMN obtained from the patients over the course of one week. These assays were performed in a blinded fashion with the authors not aware of the clinical status of the patients during the course of the week. Blood samples for the assays were obtained on hospital days 1, 4, and 7. The experiments performed were phagocytosis assays, binding of monoclonal anti-CR 1, CR3, and FcR antibodies, MPO activity and superoxide anion production. These studies were designed to study the relationship between phagocytosis, expression of opsonic receptors and the oxidative burst in patients and controls and to determine if the heightened phagocytic activity of patient PMN normalized as patients improved clinically.
Data from the first two patients studied were pooled; the third patient studied in a blind fashion was quite different from those described above. This patient had severe bacterial endocarditis with a degree of leukocytosis not found in the other patients and 42% bands. More importantly, he did not clear his septicemia during the period of study. This patient's PMN phagocytosis was abnormal at all time points although the initial increase was minimal. Unlike the other patients, this individual showed a progressive increase in the extent of phagocytosis of test particles concordant with his inability to clear his septicemia. Fig. 3 shows the mean percent phagocytosis and mean phagocytic index (PI) in the absence of azide treatment for the two patients who cleared their infection and for paired normal controls over time. Control PMN values during the week were 0-2% and 5-10 for percent phagocytosis and PI, respectively. The percentage of PMN from patients ingesting EIgG was markedly greater than that of controls on day 1; however this activity dramatically decreased over time, falling from an average of 53% phagocytosis on day 1 to 7% by day 7. The PI values fell from an average of 195.5 on day I to 10.5 on day 7 (P < 0.01 by the Bartholomew test for percent phagocytosis and phagocytic index when comparing mean differences between patients and controls) (27). The decrease in phagocytic activity by both patients' PMN, correlates with their improved clinical condition (lower temperature decreased WBC count and clearance of bacteremic state).
MPO release and superoxide anion generation. MPO release and superoxide anion generation were measured on each of 3 d ofthe longitudinal study. MPO was measured in resting PMN, PMN treated with sodium azide and in cells treated with 10% Triton X-100. Table V shows that no significant differences were found between resting patient and control PMN nor were significant differences found in total myeloperoxidase activity as assessed using PMN incubated with Triton X-100. statistical significance. There was, however, a significant increase in patient superoxide anion production between days 1 and 4, concordant with a dramatic decrease in phagocytosis (P < 0.02 by two sample t test). Table VI represents a summary of experiments in which the data from patients studied on day 1 in the longitudinal study (Table V) was combined with superoxide anion and myeloperoxidase activity obtained from two additional patients studied on day 1 of admission and their controls. MPO activity was similar for the four patients and controls, and superoxide production by nonstimulated PMN from patients and controls was also similar. Interestingly, superoxide production was consistently lower in PdBu-stimulated patient PMN; however the difference just failed to reach statistical significance.
125I monomeric IgG and 125I monoclonal antibody binding.
To assess the expression of the FcRIII, CR1 and CR3 on patient and control PMN, the binding of '251-MAbs and 1251 monomeric IgG was examined. There were no significant differences between patient and control binding of 3G8, 1 B4, or anti-Mo-1 (Table VII) , nor was there a difference in receptor expression over time in the patients during the course of the longitudinal study.
In a second group of patients studied within 36 h of hospital admission, the number of FcRI and FcRII present on the surface of patient PMN was determined. The number of highaffinity FcRl was assayed using both 125I monomeric IgG and radiolabeled MAb 32.2. Table VII represents data from both the longitudinal study examining 3G8, 1B4 and anti-Mo 1 binding along with data derived from the second group of patients studied (IV-3, 32.2, and monomeric IgG binding). No increase in the number of low-affinity FcRII was seen but five out of seven patients' PMN expressed the high-affinity Fc receptor as measured by monomeric IgG binding while two of these five patients tested for 32.2 binding were both positive.
Discussion
The critical importance of phagocytic cells in host defense has been known for a century. It is also well known that phagocytic cells can undergo activation with alterations in function of many cellular systems. Recently, various cytokines and inflammatory factors have been shown to affect the activation process. These cytokines both upregulate and downregulate many cellular processes. It is known that infection is associated with the release of many ofthese factors, and it is reasonable to expect that these factors are of importance in determining the host response to infectious agents. For this reason, it is perhaps surprising that there are relatively few studies of phagocytosis by neutrophils and monocytes from patients with infection. In previous studies both upregulation and downregulation of the phagocytic process have been reported during infection (3-6). In general, these studies have used serum opsonized targets. It is now known that such targets have a number of different opsonins on their surface, each of which interact with different membrane receptors. These various receptors behave differently in biologic systems, in part explaining the lack of uniformity of the reported data. It was, therefore, of interest to reexamine the phagocytic capacity of a selected group of patients during infection using well defined target particles that would allow for an assessment of specific receptor functions. Sheep erythrocytes, sensitized with known amounts of IgG antibody, known amounts of highly purified human C3b plus IgG, or with C3b or iC3b alone, were used as target particles in the studies reported here.
Using similar target particles, Gaither et al. recently reported that products of the oxidative burst of phagocytic cells, formed during phagocytosis of IgG sensitized targets, rapidly downregulate the normal phagocytic process (7). Patients with chronic granulomatous disease and MPO deficiency, who fail to have a normal oxidative burst, have a marked upregulation in phagocytosis (7). Stendahl and co-workers made similar observations with MPO deficient PMN and also concluded that products of the oxidative burst reduce phagocytosis (28) . It has also been shown that platelet-derived growth factor, which downregulates the normal oxidative burst, also upregulates phagocytosis (29) . It was therefore possible that products of the oxidative burst, formed during phagocytosis of bacteria, might downregulate phagocytic function in infected individuals.
In this report, we compared phagocytosis by PMN and monocytes of patients with acute bacterial infections with that of normal individuals. We confirmed our previous finding that phagocytosis by normal PMN in the absence of oxygen radical scavengers is greatly enhanced when the formation of toxic oxidative products ofthe MPO-H202-halide system is blocked, i.e., by incubation with sodium azide, a potent inhibitor of MPO. In the absence of such treatment, normal PMN expressed minimal phagocytic activity and did not phagocytize targets heavily coated with IgG antibodies. It is important to emphasize that these differences in the extent of phagocytosis do not represent differences in the rate of breakdown of the target erythrocytes. In our previous report (7), sodium azide was found to increase phagocytosis of serum-opsonized Candida, a relatively nondegradable particle, as well as EIgG. In contrast to the findings in normals, PMN from patients with acute bacterial infection showed substantial phagocytosis of both EIgG and EAC3b-IgG targets in the absence ofan inhibitor of the oxidative burst (Fig. 1) . Phenotypically, these cells are markedly upregulated above the level of activity seen in normal individuals. Interestingly, in longitudinal studies of two patients, the apparent upregulation of PMN phagocytosis was temporally related to their illness. The ability to ingest EIgG particles in the absence of sodium azide diminished over time and corresponded with the patients' clinical improvement (Fig. 3) . In a third patient, clinically extremely ill with endocarditis and staphylococcal septicemia, phagocytosis by neutrophils in the absence of azide increased progressively over the 10 d of study as the patient remained bacteremic, febrile, and clinically ill. When the extent of phagocytosis by control and patient PMN was examined in the presence of 10 mM azide, ingestion of EIgG and EAC3b-IgG was also found to be consistently greater with patient PMN (Table II ; Fig. 2 ). We also studied phagocytosis of C3b-and iC3b-coated targets. As in normal PMN, PMN from patients did not phagocytose C3b coated particles, even with as many as 100,000 C3b/ target. Interestingly, although there was no phagocytosis of iC3b-coated targets by normal PMN, 5 of 7 patients showed phagocytosis of iC3b-coated targets, although the extent of phagocytosis was low (Table III) .
In marked contrast to PMN, monocytes from infected patients did not demonstrate upregulation ofthe extent ofphagocytosis when compared with controls (Table II) , and azide was not found to enhance phagocytosis ofcontrol or patient monocytes (data not shown). Interestingly, analysis ofthe kinetics of phagocytosis revealed striking differences in the rate of ingestion by patient and control monocytes, but not PMN. Furthermore, patient monocytes ingested EIgG particles markedly faster than did control monocytes, whereas the rate of ingestion by patient and control PMN was similar (Table IV) . Thus, Along with studies of phagocytosis we examined superoxide anion production and MPO release from patient and control PMN. In contradistinction to patients with CGD that we studied previously (7) , patients with acute bacterial infection have normal mechanisms for generating superoxide and MPO in the resting state (30) (31) (32) . Solomkin et al. reported normal superoxide formation in patients with intraabdominal infections in response to FMLP but not with serum opsonized zymosan (25) . We found that overall superoxide anion production was similar in resting patient and control PMN. Superoxide anion generation was increased over baseline in both patient and control PMN upon stimulation with PDBu; and there was no significant difference (P < 0.076) in stimulated PMN from patients and controls (Table VI) . It is important to note that in the two patients studied longitudinally there was reduced superoxide production in both resting and stimulated PMN on day 1, during which time, phagocytosis was maximal for both patients (Fig. 3) . While superoxide levels in infected PMN were initially reduced, they reached supra normal values by the end of the fourth hospital day (Table V) ; and phagocytosis fell significantly by the fourth hospital day. On day 7, superoxide levels in patient PMN was similar to that of day 4, and phagocytic activity was minimal. It should be noted that, there was no significant difference by statistical analysis between patient and control PMN production of superoxide on days 1, 4, or 7. However, the increase in superoxide production by patient PMN from day 1 to day 4 was highly significant when compared to the increase seen in control PMN. It is possible that this diminished superoxide production by patient PMN early in the course ofinfection (day 1) may play a role in allowing upregulation of PMN phagocytosis during the most acute phase of bacterial infection. In contrast to superoxide anion generation, we found no significant differences in MPO release by patient and control PMN, nor was there a difference in total MPO as assessed in Triton X-100 treated PMN. Bass et al. (33) reported that a subpopulation of primed PMN is responsible for much of the increased H202 production seen in patients with acute bacterial and Candida infections. It is possible that in the patients studied here a subpopulation responsible for superoxide anion production may increase during the early phase of acute infection as the patients clinical condition improves.
It was of importance to test for differences in receptor expression as a possible factor in patient PMN upregulation. The binding of radiolabeled monoclonal antibodies to three major opsonic receptors was followed in the longitudinal studies: 3G8, 1B4, and anti-Mo-1; MAb against PMN FcRIII, and CR1, and CR3, respectively. There was no significant difference in 3G8, 1B4, or anti-Mo-I binding on any day that they were tested. In addition, utilizing radiolabeled monomeric IgG and radiolabeled MAbs, we assayed the surface expression of PMN FcRI and FcRII in a series of patients studied within 36 h of hospital admission. No increases in FcRII were seen, but a striking increase in the number of FcRI was seen both by binding of 1251 monomeric IgG and 1251 32.2, a MAb directed against the PMN high-affinity receptor (Table VII) . The increase in 1251 monomeric IgG binding was seen on 5/7 patients tested. In 2/2 patients tested, anti-FcRI binding was increased. The role of the high-affinity Fc receptor in the upregulation of the patient PMN is not yet known.
In summary, PMN and monocytes from patients with acute bacterial infection are upregulated with respect to Fc receptor-mediated phagocytosis. The total phagocytic capacity of PMN is enhanced, whereas the rate ofingestion is enhanced in monocytes of infected patients. This effect does not appear to be due to differences in the number of opsonic receptors (FcRII, FcRIII, CR1, or CR3) on PMN; however the number of FcRI is strikingly increased. A low level of CR3-mediated ingestion was observed in infected PMN but these cells were not activated to phagocytize via CR1. MPO release and total MPO content were similar in patient and control PMN. Superoxide anion generation by unstimulated patient PMN was low at a time that phagocytosis was markedly greater than that of normal PMN; it rose to levels over controls as phagocytosis decreased toward the normal range. Thus the response to infection in humans is associated with alterations in PMN phagocytic and oxidative functions. Presumably this marked upregulation in phagocytic function represents a complex physiologic response that serves to provide an important additional measure of host defense.
